Pharmacogenetics of anti-estrogen treatment of breast cancer

Cancer Treatment Reviews

Volumn 38, Issue 5, 2012, Pages 442-450

  Del Re, Marzia ^a   Michelucci, Angela ^b   Simi, Paolo ^b   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Aromatase inhibitor; CYP19A1; CYP2D6; Estrogen receptor; Pharmacogenetics; Polymorphisms; Tamoxifen

Indexed keywords

ANASTROZOLE; ANDROSTENEDIONE; ANTIESTROGEN; AROMATASE; CYTOCHROME P450 2D6; ENDOXIFEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; LETROZOLE; SULFOTRANSFERASE 1A1; TAMOXIFEN;

ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL DECISION MAKING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HORMONE RESPONSE; HUMAN; PATIENT SELECTION; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

AROMATASE; AROMATASE INHIBITORS; ARYLSULFOTRANSFERASE; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 84861193729     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.08.003     Document Type: Review

References (90)

1. Abraham J.E., Maranian M.J., Driver K.E., et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010, 12:R64.
2. Anghel A., Raica M., Marian C., et al. Combined profile of the tandem repeats CAG, TA an CA of the androgen and estrogen receptor genes in breast cancer. J Cancer Res Clin Oncol 2006, 132:727-733.
3. Baxter S.W., Choong D.Y., Eccles D.M., Campbell I.G. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001, 22:347-349.
4. Bickenbach K.A., Jaskowiak N. Aromatase inhibitors: an overview for surgeons. J Am Coll Surg 2006, 203:376-389.
5. Borges S., Desta Z., Li L., et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006, 80:61-74.
6. Boyapati S.M., Ou Shu X., Ruan Z.X., et al. Polymorphisms in ERα gene interact with estrogen receptor status in breast cancer patients. Clin Cancer Res 2005, 11:1093-1098.
7. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3:229-243.
8. Brueggemeier R.W. Update on the use of aromatase inhibitors in breast cancer. Expert Opin Pharmacother 2006, 7:1919-1930.
9. Bulun S.E., Sebastian S., Takayama K., et al. The human CYP 19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol 2003, 86:219-224.
10. Buzdar A.U. Advanced in endocrine treatment for postmenopausal women with metastatic and early breast cancer. Oncologist 2003, 8:335-341.
11. Cato A.C., Nestl A., Mink S. Rapid actions of steroids receptors in cellular signalling pathways. Sci STKE 2002, 138:Re9.
12. Chlebowski R.T. Aromatase inhibitor-associated arthralgias. J Clin Oncol 2009, 27:4932-4934.
13. Chu W., Fyles A., Sellers E.M., et al. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis 2007, 28:2139-2142.
14. Coleman R.E., Bolten W.W., Lansdown M., et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 2008, 34:275-282.
15. Colomer R., Monzo M., Tusquets I., et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008, 14:811-816.
16. Crew K.D., Greenlee H., Capodice J., et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007, 25:3877-3883.
17. Donnellan P.P., Douglas S.L., Cameron D.A., Leonard R.C. Aromatase inhibitors and arthralgia. J Clin Oncol 2001, 19:2767.
18. Dowsett M., Allred C., Quinn E., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008, 26:1059-1065.
19. Dugan S.A., Powell L.H., Kravitz H.M., et al. Musculoskeletal pain and menopausal status. Clin J Pain 2006, 22:325-331.
20. Dunning A.M., Dowsett M., Healey C.S., et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004, 96:936-945.
21. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' CollaborativeGroup.
22. Evans W.E., McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003, 348:538-549.
23. Felson D.T., Cummings S.R. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 2005, 52:2594-2598.
24. Ferro P., Forlani A., Muselli M., Pfeffer U. Alternative splicing of the human estrogen receptor alpha primary transcript: mechanisms of exon skipping. Int J Mol Med 2003, 12:355-363.
25. Fiegl H., Millinger S., Mueller-Holzner E., et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005, 65:1141-1145.
26. Fisher B., Redmond C., Brown A., et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986, 4:459-471.
27. Fortunati N. Sex hormone-binding globulin: not only a transport protein. What news is around the corner?. J Endocrinol Invest 1999, 22:223-234.
28. Garcia-Casado Z., Guerrero-Zotano A., Llombart-Cussac A., et al. A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer 2010, 10:36.
29. Garte S., Gaspari L., Alexandrie A.K., et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001, 10:1239-1248.
30. Geisler J., Haynes B., Anker G., et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002, 20:751-757.
31. Geisler J., King N., Anker G., et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998, 4:2089-2093.
32. Giacinti L., Claudio P.P., Lopez M. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006, 11:1-8.
33. Goetz M.P., Kamal A., Ames M.M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008, 83:160-166.
34. Goetz M.P., Knox S.K., Suman V.J., et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007, 101:113-121.
35. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005, 23:9312-9318.
36. Haiman C.A., Hankinson S.E., Spiegelman D., et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000, 87:204-210.
37. Heilberg I.P., Hernandez E., Alonzo E. Estrogen receptor gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Ren Fail 2005, 27:155-161.
38. Herrington D.M., Howard T.D., Brosnihan K.B., et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002, 105:1879-1882.
39. Higgins M.J., Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 2011, 62:281-293.
40. World Cancer Report 2008, IARC, World Health Organization, Geneva.
41. Ingle JN, Dowsett M, Cuzick J, Davies C. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. In: 31st Annual San Antonio breast cancer symposium; 2008 (abstract 12).
42. Ingle J.N., Schaid D.J., Goss P.E., et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010, 28:4674-4682.
43. Ingle J.N., Suman V.J., Johnson P.A., et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res 1999, 5:1642-1649.
44. Ingle J.N., Suman V.J. Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Mol Biol 2005, 95:113-119.
45. Irvin W.J., Walko C.M., Weck K.E., Ibrahim J.G., Chiu W.K., Dees E.C., et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011, doi:10.1200/JCO.2010.31.4427.
46. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97:30-39.
47. Kimchi-Sarfaty C., Oh J.M., Kim I.-W., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
48. Kristensen N.V., Harada N., Yoshimura N., et al. Genetic variant of CYP19 (aromatase) and breast cancer risk. Oncogene 2000, 1919:1329-1333.
49. Kristensen V.N., Andersen T.I., Lindblom A., et al. A rare CYP 19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998, 8:43-48.
50. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002, 54:1271-1294.
51. Lim H.S., Ju Lee H., Seok Lee K., et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007, 25:3837-3845.
52. Lloveras B, Monzo M, Colomer R, et al. Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22:507.
53. Lopez-Guerrero J.A., Garcia-Casado Z., Guerrero-Zotano A.L., et al. Corroboration of polymorphisms in the aromatase (CYP19A1) gene with response to neoadjuvant therapy with letrozole in postmenopausal women with stages II-II ER/PgR-positive breast cancer. Proc Am Soc Clin Oncol 2007, 25:602. (abstract 602).
54. Lu W.J., Xu C., Pei Z., Mayhoub A.S., Cushman M., Flockhart D.A. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat 2011, doi:10.1007/s10549.011.1699.4.
55. Ma X.C., Adjei A.A., Salavaggione O.E., et al. Human aromatase: gene resequencing and functional genomic. Cancer Res 2005, 65:1171-1182.
56. Madlensky L., Natarajan L., Tchu S., et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011, doi:10.1038/clpt.2011.32.
57. Mao J.J., Stricker C., Bruner D., et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009, 115:3631-3639.
58. Mao J.J., Su H.I., Feng R., et al. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 2011, 13:R8.
59. Menard S., Fortis S., Castiglioni F., et al. HER2 as a prognostic factor in breast cancer. Oncology 2001, 61(Suppl 2):67-72.
60. Miyoshi Y., Ando A., Hasegawa S., et al. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer 2003, 39:2531-2537.
61. Morales L., Pans S., Verschueren K., et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008, 26:3147-3152.
62. Mortimer J., Flournoy N., Livingston R.B., Stephens R.L. Aggressive adriamycin-containing regimen (PM-FAC) in estrogen receptor-negative disseminated breast cancer. Results of a Southwest Oncology Group trial. Cancer 1985, 56:2376-2380.
63. Nowell S., Sweeney C., Winters M., et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 2002, 94:1635-1640.
64. Nowell S.A., Ahn J., Rae J.M. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005, 91:249-258.
65. Onland-Moret N.C., van Gils C.H., Roest M., et al. The estrogen receptor α gene and breast cancer risk. Cancer Causes Control 2005, 16:1195-1202.
66. Osborne C.K., Schiff R. Aromatase inhibitors: future directions. J Steroids Biochem Mol Biol 2005, 95:183-187.
67. Osborne C.K., Wiebe V.J., McGuire W.L., et al. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 1992, 10:304-310.
68. Probst-Hensch N.M., Ingles S.A., Diep A.T., et al. Aromatase and breast cancer susceptibility. Endocrine Related Cancer 1999, 6:165-173.
69. Raskin L., Lejbkowicz F., Barnett-Griness O., et al. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews. Cancer Epidemiol Biomarkers Prev 2009, 18:1617-1623.
70. Ruiter R., Bijl M.J., van Schaik R.H., et al. CYP2C19.2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 2010, 11:1367-1375.
71. Sasano H., Suzuki T., Nakata T., Moryia T. New development in intracrinology of breast carcinoma. Breast Cancer 2006, 13:129-136.
72. Schroth W., Antoniadou L., Fritz P., et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007, 25:5187-5193.
73. Siegelmann-Danieli N., Buetow K.H. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 1999, 79:456-463.
74. Silva E., Kabil A., Kortenkamp A. Cross-talk between non-genomic and genomic signalling pathways-distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol 2010, 245:160-170.
75. Stearns V., Johnson M.D., Rae J.M., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95:1758-1764.
76. Stingl J.C., Parmar S., Huber-Wechselberger A. Impact of CYP2D6.4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res Opin 2010, 26:2535-2542.
77. Sun D., Chen G., Dellinger R.W., et al. Characterization of tamoxifen, 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 2006, 8:R50.
78. Thompson A.M., Johnson A., Quinlan P., et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 2011, 125:279-287.
79. Thyagarajan B., Brott M., Mink P., et al. CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence. no association in the ARIC study. Cancer Lett 2004, 207:183-189.
80. Tucker A.N., Tkaczuk K.A., Lewis L.M., et al. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett 2005, 217:61-72.
81. Walker A.H., Jaffe J.M., Gunasegaram S., et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution, implications for prostate cancer risk. Hum Mutat 1998, 12:289.
82. Wang L., Ellsworth K.A., Moon I., et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010, 70:319-328.
83. Watanabe J., Harada N., Suemasu K., et al. Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity. Pharmacogenetics 1997, 7:419-424.
84. Webb P., Nguyen P., Valentine C., Weatherman R.V., Scalan T.S., Kushner P.J. An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen. J Biol Chem 2000, 275:37552-37558.
85. Wegman P., Elingarami S., Carstensen J., et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15, tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007, 9:R7.
86. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003, 348:529-537.
87. Widschwendter M., Siegmund K.D., Muller H.M., et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004, 64:3807-3813.
88. Xu Y., Sun Y., Yao L., et al. Association between CYP2D6.10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008, 19:1423-1429.
89. Yoneda K., Tanji Y., Ikeda N., et al. Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. Cancer Lett 2002, 223-230.
90. Yu H., Shu X.O., Shi R., et al. Plasma sex steroid hormones and breast cancer risk in Chinese women. Int J Cancer 2003, 105:92-97.